

# Press Release

---

Zurich-Schlieren, Switzerland, October 18<sup>th</sup>, 2024

## Topadur Pharma AG Strengthens Executive Team Towards IPO

Topadur Pharma AG, a Swiss clinical-stage biotechnology company, today announces the appointments of PD Dr. Matthias Schäfer as Chief Innovation Officer (CIO) and Prof. Dr. Jay Siegel as Chief Research Officer (CRO).

**Matthias Schäfer** is a seasoned international leader, who uniquely combines management skills with in-depth experience in biomedical research from which he developed products and strategies with sustainable economic success. Previously, he held leadership positions as Senior Manager, Director and Business Unit Head in the healthcare industry along with an assignment as consultant and as lecturer at ETH Zurich. He holds a PhD in Biology and completed several Executive Business Trainings e.g. at the St. Gallen Management Institute (SGMI).

Matthias Schäfer: “Topadur has an innovative pipeline of drug candidates with highly effective mode of action, demonstrating significant potential as disruptive therapies of various diseases with a high medical need. I am excited to support the Topadur team in advancing the product development toward market entry with my expertise and enthusiasm”.

**Jay Siegel** brings to Topadur over 40 years of experience in molecular design and chemical synthesis research. He was previously Dean of a School of Pharmaceutical Science and Technology and Director of a Laboratory for Process Research on the synthesis of API for the Pharmaceutical Market. He earned his PhD at Princeton, did Fulbright studies at ETH, and completed a postdoc with JM Lehn at Strasbourg. Jay held a professor/director position at the University of Zurich for over 11 years. He is most recently Senior Advisor to the President of the University of Hong Kong.

Jay Siegel: “I have followed the development of Topadur and its drug pipeline for over a decade. The special physical and biological properties of these bioactive molecules present a great promise for the future of targeted therapies and multiple action agents. I am confident there are positive materials in hand and on the developmental horizon.”

“I’m excited to announce Matthias Schäfer and Jay Siegel's appointment. Together, they bring profound knowledge and sound experience in business development within healthcare. Matthias and Jay will significantly strengthen our team, adding complementary expertise. Currently, Jay has a mandate as a consultant with Topadur and will take over the full-time CRO role from early next year upon completing his current obligations in Hong Kong,” said Pascal Brenneisen, CEO Topadur Pharma AG.

# Press Release

---

## About Topadur

Topadur is a patient-oriented biotech company developing disruptive therapies for aging diseases. The Swiss-based biotech company developed the DualTOP™ technology platform consisting of new dual-acting drugs that increase cGMP levels to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Topadur's R&D portfolio consists of promising development candidates in regenerative medicine, oncology, ophthalmology and medical aesthetics. The DualTOP™ technology will contribute to promoting long healthy life.

For more information regarding Topadur Pharma AG, please visit: [www.topadur.com](http://www.topadur.com)

## Contact

Jaan Strang  
Head Project Management  
+41 44 755 44 66  
[jaan.strang@topadur.com](mailto:jaan.strang@topadur.com)

## DISCLAIMER

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of TOPADUR PHARMA AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.